{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:40:55Z","timestamp":1773261655981,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2019R1A2C1002863"],"award-info":[{"award-number":["2019R1A2C1002863"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2022R1A2C2003831"],"award-info":[{"award-number":["2022R1A2C2003831"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2025-02215037"],"award-info":[{"award-number":["RS-2025-02215037"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euros.2025.10.004","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:45:42Z","timestamp":1761133542000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effectiveness and Safety of Mirabek Sustained-release 50\u00a0mg Tablets in Korean Patients with Overactive Bladder: A Multicenter Observational Study at Tertiary General Hospitals"],"prefix":"10.1016","volume":"82","author":[{"given":"Jee Soo","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jongchan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon-Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0381","authenticated-orcid":false,"given":"Won Sik","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.10.004_b0005","article-title":"6th international consultation on incontinence","author":"Abrams","year":"2017","journal-title":"Int Continence Soc"},{"key":"10.1016\/j.euros.2025.10.004_b0010","article-title":"EAU guidelines on urinary incontinence in adults","author":"Burkhard","year":"2024","journal-title":"Eur Assoc Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0015","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0030","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JU.0000000000000807","article-title":"International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR","volume":"204","author":"Staskin","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0035","doi-asserted-by":"crossref","first-page":"795","DOI":"10.5124\/jkma.2016.59.10.795","article-title":"New pharmacotherapy for treating overactive bladder: mirabegron and botulinum toxin","volume":"59","author":"Kim","year":"2016","journal-title":"J Korean Med Assoc"},{"key":"10.1016\/j.euros.2025.10.004_b0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5489\/cuaj.3098","article-title":"Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada","volume":"9","author":"Wagg","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euros.2025.10.004_b0045","first-page":"S121","article-title":"Persistence with overactive bladder pharmacotherapy in a Medicaid population","volume":"11","author":"Shaya","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.euros.2025.10.004_b0050","first-page":"401","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"AMA Intern Med"},{"key":"10.1016\/j.euros.2025.10.004_b0055","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.euf.2024.02.002","article-title":"Risks of dementia after treatment with an anticholinergic, beta-3 agonist, or combination of both for an overactive bladder: a Korean national cohort study","volume":"10","author":"Park","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2025.10.004_b0060","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1464-410X.2006.06564.x","article-title":"The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder","volume":"98","author":"Biers","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2025.10.004_b0065","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1464-410X.2006.06679.x","article-title":"The role of the urothelium in mediating bladder responses to isoprenaline","volume":"99","author":"Murakami","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2025.10.004_b0070","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euros.2025.10.004_b0080","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/jama.2016.11237","article-title":"The high cost of prescription drugs in the United States: origins and prospects for reform","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2025.10.004_b0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/pds.1055","article-title":"What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden","volume":"14","author":"Andersson","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.euros.2025.10.004_b0090","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1377\/hlthaff.28.2.546","article-title":"Patients\u2019 perceptions of generic medications","volume":"28","author":"Shrank","year":"2009","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.euros.2025.10.004_b0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4111\/icu.20240278","article-title":"Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek\u00ae in adult patients with overactive bladder","volume":"66","author":"Park","year":"2025","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies","volume":"67","author":"Nitti","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euros.2025.10.004_b0105","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","volume":"65","author":"Maman","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0110","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4111\/icu.2019.60.2.114","article-title":"Patient utilization survey of mirabegron prescribed for overactive bladder","volume":"60","author":"Rahkola-Soisalo","year":"2019","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","article-title":"Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo","volume":"77","author":"Chapple","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12894-025-01742-6","article-title":"Satisfaction and persistence with vibegron in the first 6 months of overactive bladder treatment: interim results of the phase 4, real-world COMPOSUR study","volume":"25","author":"Dmochowski","year":"2025","journal-title":"BMC Urol"},{"key":"10.1016\/j.euros.2025.10.004_b0130","first-page":"O152","article-title":"Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: a Japanese post-marketing surveillance study","volume":"11","author":"Kato","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euros.2025.10.004_b0135","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/cells8040357","article-title":"Everything you always wanted to know about \u03b23-AR (but were afraid to ask)","volume":"8","author":"Schena","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.euros.2025.10.004_b0140","first-page":"728","article-title":"Comparing adherence and persistence across 6 chronic medication classes","volume":"15","author":"Yeaw","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.euros.2025.10.004_b0145","first-page":"S150","article-title":"Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin","volume":"11","author":"Perfetto","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.euros.2025.10.004_b0150","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40261-015-0342-2","article-title":"Impact of loss of work productivity in patients with overactive bladder treated with antimuscarinics in Spain: study in routine clinical practice conditions","volume":"35","author":"Sicras-Mainar","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.euros.2025.10.004_b0155","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.acuro.2015.09.004","article-title":"Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care: an observational baseline study","volume":"40","author":"Sicras-Mainar","year":"2016","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euros.2025.10.004_b0160","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.acuro.2014.02.001","article-title":"Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice","volume":"38","author":"Sicras-Mainar","year":"2014","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euros.2025.10.004_b0165","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1524-4733.2005.00041.x","article-title":"Persistence and adherence of medications for chronic overactive bladder\/urinary incontinence in the California Medicaid program","volume":"8","author":"Yu","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.euros.2025.10.004_b0170","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12944","article-title":"Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)","volume":"71","author":"Drake","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euros.2025.10.004_b0175","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/medicina58060825","article-title":"Impact of mirabegron administration on the blood pressure and pulse rate in patients with overactive bladder","volume":"58","author":"Ito","year":"2022","journal-title":"Medicina (Kaunas)"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325014272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325014272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:21:54Z","timestamp":1773202914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168325014272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"alternative-id":["S2666168325014272"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.10.004","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and Safety of Mirabek Sustained-release 50\u00a0mg Tablets in Korean Patients with Overactive Bladder: A Multicenter Observational Study at Tertiary General Hospitals","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}